Aclaris data due starting this month

 - Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month –

- Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 -

https://www.globenewswire.com/news-release/2023/11/06/2773930/37216/en/Aclaris-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html